Launching Combination Products: Brand extension and franchise development strategies--Aarkstore Enterprise
Aarkstore announce a new report "Launching Combination Products: Brand extension and franchise development strategies" through its vast collection of market research report.
Launching Combination Products
Brand extension and franchise development
Business Intelligence for the Pharmaceutical Industry
The portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.
Some key findings from this report... • Key cardiovascular combination product launch strategies are focused upon developing franchises within individual indications. Seven of these projects are currently in late-stage development, while three are poised to expand into other risk factors such as diabetes. • Major diabetes combination product launch strategies are concentrated in franchise development across multiple indications, two of which are currently in late-stage development. However, oral diabetes drugs will continue their expansion with brand extensions. • Single pill, fixed dose combinations will be introduced to the HIV market as dosing regimens for new therapies become established and replace current market leading combinations. Presently however, the market is still characterized by significant pill burdens. • The success of combination products is largely dependant upon the implementation of effective branding, pricing and positioning objectives. Although such issues are the primary concern of the product manager, this responsibility should be shared amongst associated product managers, therapy area heads, R&D leads, corporate planning and pricing managers, and sales and marketing.
Launching Combination Products Combination pharmaceutical products, or fixed-dose combinations (FDC’s), offer benefits to many drug classes due to the additive nature of therapeutic effect and the reduced level of side-effects associated with their use. Their core advantage however is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs. Although fixed-dose combination drugs have historically attracted disapproval from physicians, who typically prefer to determine the components and ratios of drug applications at their own discretion, a widespread acknowledgement and acceptance of these therapies has now been established. This is largely due to their effectiveness in areas such as HIV and asthma, but the successful positioning of combination products remains difficult in therapeutic areas where combination therapies only provide marginally incremental benefits. Launching Combination Products is a new report provides detailed strategic guidance for the preparation and successful execution of combination product launches. This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women’s health. Detailed case studies also provide unique insights into the brand extension and franchise development strategies of leading companies and help to identify the key success factors behind recent combination product launches.
Top five reasons to order your copy today • Understand the competitive environment for combination product launches with this report’s detailed analysis of recent, leading and future launches in key therapy areas including cardiovascular, respiratory, HIV and women’s health. • Benchmark the successful strategies of leading companies using this report’s case studies that detail a range of combination product launch tactics applied across a variety of drugs. • Formulate effective therapy area-specific combination product launch strategies with this report’s analysis of high value opportunities across a number of therapy areas. • Assess the differences between brand extensions and franchise developments and understand the strategic rationale that will determine which implementation is most effective for your company. • Develop defensive counter-strategies against combination products with this report’s examination of impending launches and explore the repositioning initiatives offered by combination strategies.
Key issues examined in this report... • Patient compliance. Fixed dose combinations provide essential convenience for patients, most notably for chronic diseases involving high pill burdens. However, improved patient compliance is more evident in some treatment settings than in others. • Cardiovascular risk factor combinations. Combinations in late stage development are attempting targeting a number of cardiovascular risk factors, such as hypertension, dyslipidemia and diabetes. Their potential impact on this broad therapeutic category remains unknown. • Cancer combinations. The use of multiple drug ‘combinations’ in the treatment of cancer is well established, most prominently with monoclonal antibody and chemotherapies. However, fixed dose combinations are difficult to establish when drugs from different classes are combined into different formulations. • HIV combinations. There are currently no leading combination therapies in late stage development for HIV, and it will take time for new therapies to be integrated into established treatment paradigms.
Your questions answered... • What are the key issues influencing combination products and successful therapy area launches? • How do combination brand strategies vary by therapy area? • What are the therapeutic and commercial drivers for developing fixed-dose combination products? • What are the differences between brand extension and franchise development strategies? • To what extent have established combination product launches affected key therapy areas? • What impact will future combination product launches have upon key therapy areas? • What are the leading combination product opportunities within key therapy areas?
Be the first to comment.